Ewha Med J.  2021 Oct;44(4):148-149. 10.12771/emj.2021.44.4.148.

Is Multidrug-resistant Extrapulmonary Tuberculosis Important? If So, What Is Our Strategy?

• Kim SE

• KMID: 2521829
• DOI: http://doi.org/10.12771/emj.2021.44.4.148

Abstract

no abstract avaliable

Reference

1. Hong SW, Park SH, Ye BD, Yang SK. 2021; Differentiating between intestinal tuberculosis and Crohn's disease may be complicated by multidrug-resistant Mycobacterium tuberculosis. Ewha Med J. 44:93–96. DOI: 10.12771/emj.2021.44.3.93.

2. World Health Organization (WHO). 2020. Global tuberculosis report 2020 [Internet]. WHO;Geneva: Available from: https://www.who.int/publications/i/item/9789240013131. cited 2021 Oct 10.

3. Lohiya S, Tripathy JP, Sagili K, Khanna V, Kumar R, Ojha A, et al. 2020; Does drug-resistant extrapulmonary tuberculosis hinder tb elimination plans? A case from Delhi, India. Trop Med Infect Dis. 5:109. DOI: 10.3390/tropicalmed5030109. PMID: 32630163. PMCID: PMC7558170.

4. Korea Disease Control and Prevention Agency (KDCA). 2021. 2021 National tuberculosis management guidelines [Internet]. KDCA;Cheongju: Available from: https://www.kdca.go.kr/board/board.es?mid=a20507020000&bid=0019&act=view&list_no=711688. cited 2021 Oct 10.

5. Joint Committee for the Revision of Korean Guidelines for Tuberculosis; Korea Centers for Disease Control and Prevention. 2020. Korean guidelines for tuberculosis. 4th ed. Korea Centers for Disease Control and Prevention;Cheongju:

6. Datta S, Bhattacherjee S. 2014; Primary multi drug resistant extra-pulmonary tuberculosis presenting as cervical lymphadenitis. J Glob Infect Dis. 6:91–92. DOI: 10.4103/0974-777X.132066. PMID: 24926174. PMCID: PMC4049050.

7. Sonambekar A, Desai D, Abraham P, Mehta V, Samant H, Joshi A, et al. 2017; Drug resistance in intestinal tuberculosis: a reason to worry? JGH Open. 1:22–24. DOI: 10.1002/jgh3.12003. PMID: 30483528. PMCID: PMC6207004.

8. Ye BD, Yang SK, Kim D, Shim TS, Kim SH, Kim MN, et al. 2012; Diagnostic sensitivity of culture and drug resistance patterns in Korean patients with intestinal tuberculosis. Int J Tuberc Lung Dis. 16:799–804. DOI: 10.5588/ijtld.11.0252. PMID: 22508109.

9. Limsrivilai J, Pausawasdi N. 2021; Intestinal tuberculosis or Crohn's disease: a review of the diagnostic models designed to differentiate between these two gastrointestinal diseases. Intest Res. 19:21–32. DOI: 10.5217/ir.2019.09142. PMID: 32311862. PMCID: PMC7873401.

10. Alrajhi S, Germain P, Martel M, Lakatos P, Bessissow T, Al-Taweel T, et al. 2020; Concordance between tuberculin skin test and interferon-gamma release assay for latent tuberculosis screening in inflammatory bowel disease. Intest Res. 18:306–314. DOI: 10.5217/ir.2019.00116. PMID: 32182640. PMCID: PMC7385575.

11. Ooi CJ, Hilmi I, Banerjee R, Chuah SW, Ng SC, Wei SC, et al. 2019; Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn's disease in Asia. Intest Res. 17:285–310. DOI: 10.5217/ir.2019.00026. PMID: 31146509. PMCID: PMC6667368.

12. Ham NS, Myung SJ. 2021; Endoscopic molecular imaging in inflammatory bowel disease. Intest Res. 19:33–44. DOI: 10.5217/ir.2019.09175. PMID: 32299156. PMCID: PMC7873406.